COMPLETED RESEARCH STUDIES

Below is an archive of all of our previously active research studies. All studies on this page are closed to enrollment. For more detailed information about these studies, look up the given NCT# in clinicaltrials.gov.

RaVeR: Prospective, Observational Safety Study of Patients with Granulomatosis with Polyangiitis (Wegener’s) or Microscopic Polyangiitis Treated with Rituximab

Study Dates: 2012-2017

NCT #: NCT01613599

Study Findings: This was a Phase IV, open-label, prospective study to characterize the long-term safety of rituximab in a 4-year observational registry of adult patients with GPA or MPA.  The study demonstrated that the safety profile of long-term (up to 4 years) repeated treatments with rituximab is consistent with the known overall safety profile of rituximab in patients treated for a shorter duration.

PEXIVAS: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

Study Dates: 2012-2019

NCT #: NCT00987389

Study Findings: This study demonstrated that the addition of plasma exchange to standard therapy does not reduce the risk for all-cause mortality or end-stage renal disease among patients with severe ANCA-associated vasculitis.

RITAZAREM: An International, Open Label, Randomized Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis

Study Dates: 2012-2020

NCT #: NCT01697267

Study Findings: This study demonstrated that patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with a prior history of relapse, who receive maintenance therapy with rituximab are more likely to remain in remission than those given azathioprine.

GiACTA: A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis

Study Dates: 2013-2018

NCT #: NCT01791153

Study Findings: This study demonstrated that weekly tocilizumab (Actemra®) treatment, initially in combination with a six-month steroid (glucocorticoid) taper, enabled significantly more patients with GCA to achieve sustained disease remission while also significantly reducing steroid exposure compared with taking steroids alone.

DCVAS: The Diagnostic and Classification Criteria for Vasculitis study

Study Dates: 2013-2018

NCT #: NCT01066208

Study Findings: This was an observational study designed to develop and validate diagnostic criteria and to improve and validate classification criteria for primary systemic vasculitis. The updated classification criteria are intended to improve the quality of future clinical trials and clinical research because patients with specific diseases will be able to be reliably grouped for studies.

MEA115921: A Double-blind, Randomised, Placebo-controlled

Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy

Study Dates: 2014-2017

NCT #: NCT02020889

Study Findings: Mepolizumab was shown to increase accrued time in remission, reduce frequency of relapse and exacerbation, and enable patients to reduce corticosteroid dose.

CLASSIC: A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Study Dates: 2014-2018

NCT #: NCT02222155

Study Findings: The goal of the CCX168 development program in AAV was to reduce or eliminate the use of chronic high dose glucocorticosteroids (steroids) in current standard of care treatment.  This study demonstrated that the study drug CCX168 (avacopan) was well tolerated in patients with ANCA-associated vasculitis when added to current standard of care treatment.  This study led to a Phase 3 study called ADVOCATE.

Mepolizumab Long-term Access Program for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-Care Therapy

Study Dates: 2016-2018

NCT #: NCT03298061

Study Findings: This study enabled subjects who participated in the MEA115921 study to continue treatment with mepolizumab.

ADVOCATE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Study Dates: 2017-2020

NCT #: NCT02994927

Study Findings: This study demonstrated that the study drug CCX168 (avacopan) can effectively improve remission rates, kidney function, and overall quality of life of patients with ANCA-associated vasculitis, compared with standard therapy with steroids.

InflaRx: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II

Study to Investigate the Safety and Efficacy of Two Different Dose Regimens of IFX-1 as Add-On to Standard of Care in Subjects with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Study Dates: 2018-2021

NCT #: NCT03712345

Study Findings: This was a clinical trial to determine the effectiveness and safety of the investigational drug IFX-1 in treating patients with GPA and MPA. The study investigated two different doses of the study drug compared with a placebo when given in combination with standard of care treatments. 

 

Study results are pending.

TEMPOTrimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis with Polyangiitis

Study Dates: 2019-2021

NCT #: NCT03919435

Study Findings: Study results are pending.